Synthetic biology
Early commercialmomentum 341,313 papers in 3 months (-12% yearly)$1.1B raised in 12 months24 companies
Engineering living cells and DNA like a technology: writing genes, redesigning organisms and designing new proteins with AI.
Why early commercial: Generate Biomedicines, whose drug candidates are engineered with generative AI, went public on Nasdaq in a $400M IPO while running Phase 3 trials. Feb 26, 2026
Dots under a month: dated events tracked here that month.
25 events
About synthetic biology here
- Sub-areas
- DNA synthesis, AI protein design, Genome language models, Biomanufacturing, Synthetic genomics, Cell engineering platforms, Biosecurity screening
- Stage evidence
- Early commercial, Feb 26, 2026: Generate Biomedicines, whose drug candidates are engineered with generative AI, went public on Nasdaq in a $400M IPO while running Phase 3 trials. generatebiomedicines.com
- Momentum
- 34 of 100: the mean of its ranks among the tracked fields for paper growth (25), funding in 12 months (44) and events in 90 days (34). Method
- Papers
- 5,903 in the 12 months ending two months ago, -12% against the 12 before (OpenAlex topics, journal and conference papers).
- Tracked here since
- Sep 25, 2026
Changes to this field
| Date | Change | ||
|---|---|---|---|
| Sep 25, 2026 | Synthetic biologyTechnology: Added | seed | generatebiomedicines.com |